Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek™), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: Final results of a multicenter compassionate use trial

Sima Jeha; H. Kantarjian; D. Irwin; V. Shen; S. Shenoy; S. Blaney; B. Camitta; C. H. Pui

doi:10.1038/sj.leu.2403566

Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek™), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: Final results of a multicenter compassionate use trial

Sima Jeha, H. Kantarjian, D. Irwin, V. Shen, S. Shenoy, S. Blaney, B. Camitta, C. H. Pui

Research output: Contribution to journal › Article › peer-review

142 Scopus citations

Abstract

The recombinant urate oxidase, rasburicase (Elitek™, Sanofi-Synthelabo, Inc.), has recently received regulatory approval for the prevention and treatment of hyperuricemia in children with leukemia, lymphoma, and solid tumors. Prior to approval, 682 children and 387 adults in the US and Canada received rasburicase on compassionate-use basis. Uric acid concentration declined rapidly in both adult and pediatric patients after rasburicase treatment. Similar responses were observed in patients treated with subsequent courses. Possible drug-related adverse events, including allergic reactions, were uncommon. These data confirm that rasburicase is effective and safe for the treatment and prophylaxis of children and adults with malignancy-associated hyperuricemia.

Original language	English
Pages (from-to)	34-38
Number of pages	5
Journal	Leukemia
Volume	19
Issue number	1
DOIs	https://doi.org/10.1038/sj.leu.2403566
State	Published - Jan 2005

Keywords

Elitek™
Hyperuricemia
Rasburicase
Tumor lysis
Urate oxidase
Uric acid

Access to Document

10.1038/sj.leu.2403566

Fingerprint

Dive into the research topics of 'Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek™), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: Final results of a multicenter compassionate use trial'. Together they form a unique fingerprint.

Cite this

Jeha, S., Kantarjian, H., Irwin, D., Shen, V., Shenoy, S., Blaney, S., Camitta, B., & Pui, C. H. (2005). Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek™), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: Final results of a multicenter compassionate use trial. Leukemia, 19(1), 34-38. https://doi.org/10.1038/sj.leu.2403566

@article{2d984f29fb2f4c2f9fac71cf1268ab39,

title = "Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek{\texttrademark}), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: Final results of a multicenter compassionate use trial",

abstract = "The recombinant urate oxidase, rasburicase (Elitek{\texttrademark}, Sanofi-Synthelabo, Inc.), has recently received regulatory approval for the prevention and treatment of hyperuricemia in children with leukemia, lymphoma, and solid tumors. Prior to approval, 682 children and 387 adults in the US and Canada received rasburicase on compassionate-use basis. Uric acid concentration declined rapidly in both adult and pediatric patients after rasburicase treatment. Similar responses were observed in patients treated with subsequent courses. Possible drug-related adverse events, including allergic reactions, were uncommon. These data confirm that rasburicase is effective and safe for the treatment and prophylaxis of children and adults with malignancy-associated hyperuricemia.",

keywords = "Elitek{\texttrademark}, Hyperuricemia, Rasburicase, Tumor lysis, Urate oxidase, Uric acid",

author = "Sima Jeha and H. Kantarjian and D. Irwin and V. Shen and S. Shenoy and S. Blaney and B. Camitta and Pui, {C. H.}",

note = "Funding Information: This work was supported in part by grant CA-21765 from the National Cancer Institute, a grant from Sanofi-Synthelabo, Inc., a Center of Excellence grant from the State of Tennessee and American Lebanese Syrian Associated Charities (ALSAC). C-H Pui is the American Cancer Society FM Kirby Clinical Research Professor.",

year = "2005",

month = jan,

doi = "10.1038/sj.leu.2403566",

language = "English",

volume = "19",

pages = "34--38",

journal = "Leukemia",

issn = "0887-6924",

number = "1",

}

Jeha, S, Kantarjian, H, Irwin, D, Shen, V, Shenoy, S, Blaney, S, Camitta, B & Pui, CH 2005, 'Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek™), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: Final results of a multicenter compassionate use trial', Leukemia, vol. 19, no. 1, pp. 34-38. https://doi.org/10.1038/sj.leu.2403566

Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek™), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: Final results of a multicenter compassionate use trial. / Jeha, Sima; Kantarjian, H.; Irwin, D. et al.
In: Leukemia, Vol. 19, No. 1, 01.2005, p. 34-38.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek™), in the management of malignancy-associated hyperuricemia in pediatric and adult patients

T2 - Final results of a multicenter compassionate use trial

AU - Jeha, Sima

AU - Kantarjian, H.

AU - Irwin, D.

AU - Shen, V.

AU - Shenoy, S.

AU - Blaney, S.

AU - Camitta, B.

AU - Pui, C. H.

N1 - Funding Information: This work was supported in part by grant CA-21765 from the National Cancer Institute, a grant from Sanofi-Synthelabo, Inc., a Center of Excellence grant from the State of Tennessee and American Lebanese Syrian Associated Charities (ALSAC). C-H Pui is the American Cancer Society FM Kirby Clinical Research Professor.

PY - 2005/1

Y1 - 2005/1

N2 - The recombinant urate oxidase, rasburicase (Elitek™, Sanofi-Synthelabo, Inc.), has recently received regulatory approval for the prevention and treatment of hyperuricemia in children with leukemia, lymphoma, and solid tumors. Prior to approval, 682 children and 387 adults in the US and Canada received rasburicase on compassionate-use basis. Uric acid concentration declined rapidly in both adult and pediatric patients after rasburicase treatment. Similar responses were observed in patients treated with subsequent courses. Possible drug-related adverse events, including allergic reactions, were uncommon. These data confirm that rasburicase is effective and safe for the treatment and prophylaxis of children and adults with malignancy-associated hyperuricemia.

AB - The recombinant urate oxidase, rasburicase (Elitek™, Sanofi-Synthelabo, Inc.), has recently received regulatory approval for the prevention and treatment of hyperuricemia in children with leukemia, lymphoma, and solid tumors. Prior to approval, 682 children and 387 adults in the US and Canada received rasburicase on compassionate-use basis. Uric acid concentration declined rapidly in both adult and pediatric patients after rasburicase treatment. Similar responses were observed in patients treated with subsequent courses. Possible drug-related adverse events, including allergic reactions, were uncommon. These data confirm that rasburicase is effective and safe for the treatment and prophylaxis of children and adults with malignancy-associated hyperuricemia.

KW - Elitek™

KW - Hyperuricemia

KW - Rasburicase

KW - Tumor lysis

KW - Urate oxidase

KW - Uric acid

UR - http://www.scopus.com/inward/record.url?scp=11844278229&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2403566

DO - 10.1038/sj.leu.2403566

M3 - Article

C2 - 15510203

AN - SCOPUS:11844278229

SN - 0887-6924

VL - 19

SP - 34

EP - 38

JO - Leukemia

JF - Leukemia

IS - 1

ER -

Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek™), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: Final results of a multicenter compassionate use trial

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this